B7-H1 Pathway and Its Role in the Evasion of Tumor Immunity

Overview

Journal J Mol Med (Berl)

Specialty General Medicine

Date 2003 May 2

PMID 12721664

Citations 124

Authors

Haidong Dong

Lieping Chen

Affiliations

Soon will be listed here.

Abstract

B7-H1 is a recently identified member of the B7 family molecules. Upon ligation to its receptors on T cells it regulates activation and differentiation of T cells. B7-H1 preferentially costimulates IL-10 production in resting T cells and further induces the apoptosis of activated T cells. PD-1 is a receptor of B7-H1 and is shown to mediate the inhibition of activated T cell response, presumably by inhibiting cell cycle progression. The expression of B7-H1 protein is limited to macrophage lineage of cells in normal tissues, although its mRNA transcription is found in a broad range of tissues. In contrast, B7-H1 is abundant in various human cancers. The tumor-associated B7-H1 increases apoptosis of antigen specific T cells, leading to growth of immunogenic tumor growth in vivo. Current data suggest that B7-H1 regulates the organ-specific tolerance in normal tissue and may contribute to immune evasion by cancers. Selective manipulation of B7-H1 pathway thus aids in the design of new regimens in the treatment of human autoimmune disease and the control of malignant cancers.

Citing Articles

Advancing Radiobiology: Investigating the Effects of Photon, Proton, and Carbon-Ion Irradiation on PANC-1 Cells in 2D and 3D Tumor Models.

Charalampopoulou A, Barcellini A, Magro G, Bellini A, Borgna S, Fulgini G Curr Oncol. 2025; 32(1.

PMID: 39851965 PMC: 11763791. DOI: 10.3390/curroncol32010049.

A machine learning-based immune response signature to facilitate prognosis prediction in patients with endometrial cancer.

Wang X, Guan J, Feng L, Li Q, Zhao L, Li Y Sci Rep. 2024; 14(1):30801.

PMID: 39730507 PMC: 11680691. DOI: 10.1038/s41598-024-81040-7.

Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV-GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors.

Davar D, Carneiro B, Dy G, Sheth S, Borad M, Harrington K J Immunother Cancer. 2024; 12(11.

PMID: 39551600 PMC: 11574399. DOI: 10.1136/jitc-2024-009336.

The role of programmed death receptor (PD-)1/PD-ligand (L)1 in periodontitis and cancer.

Groeger S, Meyle J Periodontol 2000. 2024; 96(1):150-169.

PMID: 38351432 PMC: 11579837. DOI: 10.1111/prd.12548.

Phase 2 study of PD-1 blockade following autologous transplantation for patients with AML ineligible for allogeneic transplant.

Solomon S, Solh M, Morris L, Holland H, Bachier-Rodriguez L, Zhang X Blood Adv. 2023; 7(18):5215-5224.

PMID: 37379271 PMC: 10500475. DOI: 10.1182/bloodadvances.2023010477.

References

Jeannin P, Delneste Y, Gauchat J, Ellis J, Bonnefoy J . CD86 (B7-2) on human B cells. A functional role in proliferation and selective differentiation into IgE- and IgG4-producing cells. J Biol Chem. 1997; 272(25):15613-9. DOI: 10.1074/jbc.272.25.15613. View

Smyth M, Godfrey D, Trapani J . A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol. 2001; 2(4):293-9. DOI: 10.1038/86297. View

Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H . Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996; 8(5):765-72. DOI: 10.1093/intimm/8.5.765. View

Chen L, McGowan P, Ashe S, Johnston J, Hellstrom I, Hellstrom K . B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum. Cancer Res. 1994; 54(20):5420-3. View

Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T . PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci U S A. 2001; 98(24):13866-71. PMC: 61133. DOI: 10.1073/pnas.231486598. View

Dunn G, Bruce A, Ikeda H, Old L, Schreiber R . Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3(11):991-8. DOI: 10.1038/ni1102-991. View

Ishida Y, Agata Y, Shibahara K, Honjo T . Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992; 11(11):3887-95. PMC: 556898. DOI: 10.1002/j.1460-2075.1992.tb05481.x. View

Ishida M, Iwai Y, Tanaka Y, Okazaki T, Freeman G, Minato N . Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunol Lett. 2002; 84(1):57-62. DOI: 10.1016/s0165-2478(02)00142-6. View

Khong H, Restifo N . Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol. 2002; 3(11):999-1005. PMC: 1508168. DOI: 10.1038/ni1102-999. View

10.

Cohen P, Peng L, Kjaergaard J, Plautz G, Finke J, Koski G . T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance. Crit Rev Immunol. 2001; 21(1-3):215-48. View

11.

DSouza S, Rimoldi D, Lienard D, Lejeune F, Cerottini J, Romero P . Circulating Melan-A/Mart-1 specific cytolytic T lymphocyte precursors in HLA-A2+ melanoma patients have a memory phenotype. Int J Cancer. 1998; 78(6):699-706. DOI: 10.1002/(sici)1097-0215(19981209)78:6<699::aid-ijc6>3.0.co;2-u. View

12.

Lollini P, Forni G . Specific and nonspecific immunity in the prevention of spontaneous tumours. Immunol Today. 1999; 20(8):347-50. DOI: 10.1016/s0167-5699(99)01450-4. View

13.

Bleul C, Boehm T . Laser capture microdissection-based expression profiling identifies PD1-ligand as a target of the nude locus gene product. Eur J Immunol. 2001; 31(8):2497-503. DOI: 10.1002/1521-4141(200108)31:8<2497::aid-immu2497>3.0.co;2-j. View

14.

Dong H, Strome S, Matteson E, Moder K, Flies D, Zhu G . Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. J Clin Invest. 2003; 111(3):363-70. PMC: 151851. DOI: 10.1172/JCI16015. View

15.

Pecher G, Haring A, Kaiser L, Thiel E . Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial. Cancer Immunol Immunother. 2002; 51(11-12):669-73. PMC: 11034218. DOI: 10.1007/s00262-002-0317-z. View

16.

Jantzer P, Schendel D . Human renal cell carcinoma antigen-specific CTLs: antigen-driven selection and long-term persistence in vivo. Cancer Res. 1998; 58(14):3078-86. View

17.

Ferrone S, Finerty J, Jaffee E, Nabel G . How much longer will tumour cells fool the immune system?. Immunol Today. 2000; 21(2):70-2. DOI: 10.1016/s0167-5699(99)01569-8. View

18.

Chambers C, Kuhns M, Egen J, Allison J . CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol. 2001; 19:565-94. DOI: 10.1146/annurev.immunol.19.1.565. View

19.

Nishimura H, Honjo T, Minato N . Facilitation of beta selection and modification of positive selection in the thymus of PD-1-deficient mice. J Exp Med. 2000; 191(5):891-8. PMC: 2195853. DOI: 10.1084/jem.191.5.891. View

20.

Melero I, Shuford W, Newby S, Aruffo A, Ledbetter J, Hellstrom K . Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med. 1997; 3(6):682-5. DOI: 10.1038/nm0697-682. View